Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC raised its holdings in Bristol-Myers Squibb (NYSE:BMY) by 34.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 446,364 shares of the biopharmaceutical company’s stock after purchasing an additional 115,361 shares during the quarter. Natixis Advisors LLC’s holdings in Bristol-Myers Squibb were worth $23,095,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in BMY. Bessemer Group Inc. raised its stake in shares of Bristol-Myers Squibb by 16.3% during the first quarter. Bessemer Group Inc. now owns 159,066 shares of the biopharmaceutical company’s stock worth $8,625,000 after purchasing an additional 22,286 shares during the last quarter. Lake Street Advisors Group LLC raised its position in Bristol-Myers Squibb by 54.7% during the 1st quarter. Lake Street Advisors Group LLC now owns 13,530 shares of the biopharmaceutical company’s stock worth $734,000 after buying an additional 4,784 shares during the last quarter. Pitcairn Co. raised its position in Bristol-Myers Squibb by 152.3% during the 1st quarter. Pitcairn Co. now owns 48,250 shares of the biopharmaceutical company’s stock worth $2,617,000 after buying an additional 29,128 shares during the last quarter. Ossiam lifted its stake in shares of Bristol-Myers Squibb by 31.7% in the 1st quarter. Ossiam now owns 88,183 shares of the biopharmaceutical company’s stock worth $4,782,000 after acquiring an additional 21,234 shares during the period. Finally, Leelyn Smith LLC boosted its holdings in shares of Bristol-Myers Squibb by 4.6% in the first quarter. Leelyn Smith LLC now owns 38,525 shares of the biopharmaceutical company’s stock valued at $2,089,000 after acquiring an additional 1,681 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Stock Up 1.0 %

BMY stock opened at $56.81 on Tuesday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08. The stock has a market capitalization of $115.22 billion, a P/E ratio of -15.82, a PEG ratio of 15.23 and a beta of 0.44. The company has a 50 day moving average price of $52.90 and a two-hundred day moving average price of $47.37. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. During the same period in the prior year, the firm posted $2.00 earnings per share. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.22%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s payout ratio is currently -66.85%.

Analyst Ratings Changes

A number of brokerages recently commented on BMY. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $55.00 to $73.00 in a research note on Tuesday, November 12th. Wolfe Research began coverage on Bristol-Myers Squibb in a report on Friday. They set a “peer perform” rating on the stock. UBS Group raised their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, October 9th. Finally, BMO Capital Markets upped their price target on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $54.07.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.